新型精神分裂症治疗方法满足了未被满足的临床需求。
New Schizophrenia Treatments Address Unmet Clinical Needs.
作者信息
Fellner Chris
出版信息
P T. 2017 Feb;42(2):130-134.
Abstract
We present several novel drugs in development for enhancing cognition, treating negative symptoms, and providing improved options for treatment-resistant patients. Drug makers aim to enhance safety profiles and increase patient compliance to therapy.
摘要
我们展示了几种正在研发的新型药物，用于增强认知、治疗阴性症状，并为难治性患者提供更好的治疗选择。制药商旨在提高安全性并提高患者对治疗的依从性。
相似文献
1
New Schizophrenia Treatments Address Unmet Clinical Needs.
P T. 2017 Feb;42(2):130-134.
2
Unmet Needs in Schizophrenia.
CNS Neurol Disord Drug Targets. 2017;16(8):870-884. doi: 10.2174/1871527316666170803143927.
3
Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness.
J Clin Psychiatry. 2006 Jul;67(7):e03. doi: 10.4088/jcp.0706e03.
4
Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study.
BMC Psychiatry. 2018 Aug 13;18(1):253. doi: 10.1186/s12888-018-1833-5.
5
Treatment-resistant schizophrenia--the role of clozapine.
Curr Med Res Opin. 1997;14(1):1-20. doi: 10.1185/03007999709113338.
6
What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
BMC Med Ethics. 2019 Nov 9;20(1):80. doi: 10.1186/s12910-019-0420-8.
7
Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers.
Expert Opin Investig Drugs. 2012 Jan;21(1):7-14. doi: 10.1517/13543784.2012.634798. Epub 2011 Nov 8.
8
NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update.
Neuropharmacology. 2018 Nov;142:41-62. doi: 10.1016/j.neuropharm.2017.11.045. Epub 2017 Nov 28.
9
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
Mol Psychiatry. 2012 Dec;17(12):1206-27. doi: 10.1038/mp.2012.47. Epub 2012 May 15.
10
Conceptualization and treatment of negative symptoms in schizophrenia.
World J Psychiatry. 2015 Dec 22;5(4):352-61. doi: 10.5498/wjp.v5.i4.352.
引用本文的文献
1
Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: Claims-linked chart study.
J Manag Care Spec Pharm. 2024 Jul;30(7):698-709. doi: 10.18553/jmcp.2024.23319. Epub 2024 May 8.
2
Design, Development, Evaluation, and In Vivo Performance of Buccal Films Embedded with Paliperidone-Loaded Nanostructured Lipid Carriers.
Pharmaceutics. 2023 Oct 25;15(11):2530. doi: 10.3390/pharmaceutics15112530.
3
Investigating the symptomatic and morphological changes in the brain based on pre and post-treatment: A critical review from clinical to neuroimaging studies on schizophrenia.
IBRO Neurosci Rep. 2023 Mar 24;14:366-374. doi: 10.1016/j.ibneur.2023.03.008. eCollection 2023 Jun.
4
Current GMP standards for the production of vaccines and antibodies: An overview.
Front Public Health. 2022 Nov 3;10:1021905. doi: 10.3389/fpubh.2022.1021905. eCollection 2022.
5
Long-lasting rescue of schizophrenia-relevant cognitive impairments via risperidone-loaded microPlates.
Drug Deliv Transl Res. 2022 Aug;12(8):1829-1842. doi: 10.1007/s13346-021-01099-x. Epub 2022 Jan 1.
6
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics.
Neurosci Biobehav Rev. 2022 Jan;132:324-361. doi: 10.1016/j.neubiorev.2021.11.032. Epub 2021 Nov 24.
7
Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.
J Clin Pharmacol. 2019 May;59(5):731-747. doi: 10.1002/jcph.1365. Epub 2019 Jan 24.
8
A narrative review of the success of intramuscular gluteal injections and its impact in psychiatry.
Biodes Manuf. 2018;1(3):161-170. doi: 10.1007/s42242-018-0018-x. Epub 2018 Jul 27.
本文引用的文献
1
Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
JAMA Psychiatry. 2013 Dec;70(12):1267-75. doi: 10.1001/jamapsychiatry.2013.2159.
2
The nature of relapse in schizophrenia.
BMC Psychiatry. 2013 Feb 8;13:50. doi: 10.1186/1471-244X-13-50.
3
Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses.
CNS Spectr. 2013 Apr;18(2):82-9. doi: 10.1017/S1092852912000806. Epub 2012 Dec 20.
4
Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies.
Schizophr Res. 2012 Aug;139(1-3):116-28. doi: 10.1016/j.schres.2012.05.007. Epub 2012 Jun 1.
5
Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis.
J Clin Psychiatry. 2010 Apr;71(4):411-8. doi: 10.4088/JCP.08r04808yel. Epub 2010 Feb 23.
6
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.
Schizophr Bull. 2010 Jan;36(1):71-93. doi: 10.1093/schbul/sbp116. Epub 2009 Dec 2.
7
Clozapine versus typical neuroleptic medication for schizophrenia.
Cochrane Database Syst Rev. 2009 Jan 21;2009(1):CD000059. doi: 10.1002/14651858.CD000059.pub2.
8
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.
Lancet. 2009 Jan 3;373(9657):31-41. doi: 10.1016/S0140-6736(08)61764-X. Epub 2008 Dec 6.
9
Clozapine-induced seizures: recognition and treatment.
Can J Psychiatry. 2007 Jul;52(7):457-63. doi: 10.1177/070674370705200708.
10
Practice guideline for the treatment of patients with schizophrenia, second edition.
Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56.
Zotero 插件